Scoop: On­copep­tides CEO ‘lean­ing to­ward’ giv­ing in to FDA with­draw­al re­quest amid ‘piss­ing con­test’ with reg­u­la­tors

On­copep­tides CEO Jakob Lind­berg is “lean­ing to­ward” com­ply­ing with the FDA’s re­quest to for­mal­ly and com­plete­ly pull its can­cer drug Pepax­to, he told End­points News …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER